Long term stability of paraoxonase-1 and high-density lipoprotein in human serum

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Beekhof, Piet K ^a   Gorshunska, Maryana ^b   Jansen, Eugène H J M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

Author keywords

High density lipoprotein; Paraoxonase; Serum; Stability; Storage

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; ENZYME STABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; PROTEIN STABILITY; THERMOSTABILITY; TIME;

ARYLDIALKYLPHOSPHATASE; CRYOPRESERVATION; HUMANS; LIPOPROTEINS, HDL; PROTEIN STABILITY; SERUM; TEMPERATURE;

EID: 84860792054     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-53     Document Type: Article

References (12)

1. Human PON1, a biomarker of risk of disease and exposure. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP, Chem Biol Interact 2010 187 355 361 10.1016/j.cbi.2010.03.033 20338154
2. Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development. Tavori H, Rosenblat M, Vaya J, Aviram M, Clinical Lipidology 2010 5 685 697 10.2217/clp.10.57
3. Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus. Camuzcuoglu H, Toy H, Cakir H, Celik H, Erel O, J Womens Health 2009 18 1435 1439 10.1089/jwh.2008.1213
4. Q192R polymorphism of PON-1 gene in type 2 diabetes patients. Gorshunskaya M, Karachentsev Y, Atramentova L, Tyzhnenko T, Kravchun N, Pochernyaev A, Poltorak V, Cytol Genet 2011 45 38 40 10.3103/S0095452711010087
5. Paraoxonase 1-192 phenotype and lower paraoxonase 1 activity are associated with increased risk of Type 2 diabetes (the CODAM Study). van den Berg SW, Jansen EHJM, Kruijshoop M, Beekhof PK, Blaak E, van der Kallen CJ, van Greevenbroek MMJ, Feskens EJM, Diabet Med 2008 25 186 193 10.1111/j.1464-5491. 2007.02328.x 18290860
6. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S, Clin Chem Lab Med 2011 49 61 67 20961187
7. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation and cholesterol efflux. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS, J Lipid Res 2006 47 2492 2502 10.1194/jlr.M600297-JLR200 16914770
8. The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Loued S, Isabelle M, Berrougui H, Khalil A, Life Sci 2012 90 82 88 10.1016/j.lfs.2011.10.018 22067439
9. Effect of dilution on high-density lipoprotein associated paraoxonase-1 activity. Mackness M, Mackness B, Clin Biochem 2011 44 1270 1271 10.1016/j.clinbiochem.2011.08.002 21854764
10. Paraoxonase 1 R/Q alleles are associated with differential accumulation of saturated versus 20:5n3 fatty acid in human adipose tissue. Zafiropoulos A, Linardakis M, Jansen EHJM, Tsatsakis AM, Kafatos A, Tzanakakis GN, J Lipid Res 2010 51 1991 2000 10.1194/jlr.P004960 20133274
11. Validation of PON1 enzyme activity assays for longitudinal studies. Huen K, Richter R, Furlong C, Eskenazi B, Holland N, Clin Chim Acta 2009 402 67 74 10.1016/j.cca.2008.12.019 19146843
12. Indications that paraoxonase-1 contributes to plasma high-density lipoprotein levels in familial hypercholesterolemia. van Himbergen TM, Roest M, de Graaf J, Jansen EHJM, Hattori H, Kastelein JJP, Voorbij HAM, Stalenhoef AFH, van Tits LJH, J Lipid Res 2005 46 445 451 15576850